S07-2010 | pan-AKR1C inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $80.00 | ||
| 25 mg | $270.00 |
S07-2010 (1223194-71-5) is a pan-aldo-keto reductase 1C (AKR1C) inhibitor (IC50’s for AKR1C isoforms: 1C1 = 470 nM, 1C2 = 730 nM, 1C3 = 190 nM, 1C4 = 360 nM). Dysregulated AKR1C3 expression (and overexpression of all AKR1C isoforms in general) is related to resistance to radio- and chemotherapy in various tumor types and is associated with development of and poor prognosis in many cancers. S07-2010 displayed cytotoxicity to doxorubicin-resistant MCF-7 cells (IC50 = 127.5 µM) and cisplatin-resistant A549 cells (IC50 = 5.51 µM). Combination treatment of chemotherapeutic agents and S07-2010 showed synergistic effects in drug-resistant cell lines.
References/Citations:
- He et al. (2022), Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance; ACS Med. Chem. Lett. 13 1286
C19H21N3O3S
98% by TLC NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
S07-2010 (1223194-71-5) is a pan-aldo-keto reductase 1C (AKR1C) inhibitor (IC50’s for AKR1C isoforms: 1C1 = 470 nM, 1C2 = 730 nM, 1C3 = 190 nM, 1C4 = 360 nM). Dysregulated AKR1C3 expression (and overexpression of all AKR1C isoforms in general) is related to resistance to radio- and chemotherapy in various tumor types and is associated with development of and poor prognosis in many cancers. S07-2010 displayed cytotoxicity to doxorubicin-resistant MCF-7 cells (IC50 = 127.5 µM) and cisplatin-resistant A549 cells (IC50 = 5.51 µM). Combination treatment of chemotherapeutic agents and S07-2010 showed synergistic effects in drug-resistant cell lines.
References/Citations:
- He et al. (2022), Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance; ACS Med. Chem. Lett. 13 1286
Related products
-
BI 2536 | Dual Plk/BRD4 inhibitor – Destabilizes Myc
From $75.00CAS:755038-02-9Catalog Number:10-4121Activity:Dual Plk/BRD4 inhibitor – Destabilizes MycChemical Name:4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamideMolecular Weight:521.67Molecular Formula:C28H39N7O3Solubility:Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)Physical Properties:Off-white solidPurity:97% by HPLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
Levetiracetam | Anticonvulsant
From $45.00CAS:102767-28-2Catalog Number:10-2040Activity:AnticonvulsantChemical Name:2(S)-(2-Oxopyrrolidin-1-yl)butyramideMolecular Weight:170.21Molecular Formula:C29H14N2O2Solubility:Soluble in DMSO (up to at least 25 mg/ml).Physical Properties:White solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.Shipping Code:RT -
PNU 74654 | Wnt pathway blocker
From $55.00CAS:113906-27-7Catalog Number:10-4519Activity:Wnt pathway blockerChemical Name:2-Phenoxybenzoic acid [(5-methyl-2-furanyl)methylene]hydrazideMolecular Weight:320.35Molecular Formula:C19H16N2O3Solubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:Off-white solidPurity:>98% by TLC
NMR (conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
